Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Gastrinoma 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Carcinoma, Islet Cell 1

Interventions

Trastuzumab 2Streptozocin 2tipifarnib 1romidepsin 1Sorafenib 1Pantoprazole 1Oxaliplatin 1Omeprazole 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Fluorouracil 1Floxuridine 1Doxorubicin 1Cisplatin 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Gastrinoma × Streptozocin × Clear all
NCT00602082 2013-08-07

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00001165 2008-03-04

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
999 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Zollinger-Ellison Syndrome, Gastrinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡